Ameet Sarpatwari, J.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drugs, Generic | 35 | 2024 | 457 | 8.610 |
Why?
|
Drug Costs | 35 | 2024 | 1196 | 7.950 |
Why?
|
Drug Industry | 32 | 2024 | 791 | 7.040 |
Why?
|
Prescription Drugs | 25 | 2024 | 635 | 6.770 |
Why?
|
Drug Approval | 30 | 2024 | 820 | 6.070 |
Why?
|
Patents as Topic | 15 | 2024 | 111 | 5.040 |
Why?
|
United States Food and Drug Administration | 35 | 2024 | 1672 | 3.890 |
Why?
|
Economic Competition | 11 | 2024 | 223 | 3.480 |
Why?
|
Government Regulation | 10 | 2022 | 525 | 2.390 |
Why?
|
Drugs, Investigational | 6 | 2020 | 211 | 2.250 |
Why?
|
Pharmaceutical Preparations | 7 | 2024 | 1085 | 2.250 |
Why?
|
Orphan Drug Production | 4 | 2020 | 48 | 2.060 |
Why?
|
Legislation, Drug | 5 | 2024 | 216 | 1.970 |
Why?
|
Rare Diseases | 7 | 2021 | 630 | 1.910 |
Why?
|
State Government | 4 | 2022 | 388 | 1.740 |
Why?
|
Drug Substitution | 5 | 2022 | 292 | 1.680 |
Why?
|
Government Agencies | 2 | 2023 | 161 | 1.510 |
Why?
|
Costs and Cost Analysis | 12 | 2022 | 1666 | 1.470 |
Why?
|
Commerce | 5 | 2024 | 614 | 1.460 |
Why?
|
Mifepristone | 3 | 2023 | 151 | 1.440 |
Why?
|
United States | 88 | 2024 | 72971 | 1.420 |
Why?
|
Public Sector | 2 | 2021 | 266 | 1.240 |
Why?
|
Pharmacists | 4 | 2022 | 261 | 1.230 |
Why?
|
Federal Government | 5 | 2024 | 266 | 1.230 |
Why?
|
Biological Products | 4 | 2021 | 948 | 1.160 |
Why?
|
Financing, Government | 3 | 2020 | 473 | 1.110 |
Why?
|
State Health Plans | 2 | 2018 | 220 | 1.010 |
Why?
|
Neglected Diseases | 2 | 2016 | 67 | 0.980 |
Why?
|
Drug and Narcotic Control | 3 | 2024 | 145 | 0.970 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 4 | 2014 | 245 | 0.930 |
Why?
|
Organizations, Nonprofit | 2 | 2021 | 105 | 0.870 |
Why?
|
Health Services Accessibility | 7 | 2022 | 5519 | 0.870 |
Why?
|
Patient Preference | 3 | 2020 | 947 | 0.860 |
Why?
|
National Institutes of Health (U.S.) | 4 | 2024 | 793 | 0.840 |
Why?
|
Sodium Oxybate | 1 | 2023 | 36 | 0.840 |
Why?
|
Research Support as Topic | 4 | 2020 | 697 | 0.820 |
Why?
|
Economics, Pharmaceutical | 2 | 2020 | 88 | 0.820 |
Why?
|
Teratogens | 1 | 2023 | 119 | 0.810 |
Why?
|
Health Expenditures | 6 | 2021 | 2390 | 0.810 |
Why?
|
Confidentiality | 3 | 2017 | 607 | 0.790 |
Why?
|
Abortifacient Agents, Steroidal | 1 | 2022 | 22 | 0.780 |
Why?
|
Adjuvants, Anesthesia | 1 | 2022 | 58 | 0.770 |
Why?
|
Reproductive Rights | 1 | 2022 | 31 | 0.770 |
Why?
|
Physicians | 5 | 2024 | 4593 | 0.750 |
Why?
|
Advisory Committees | 2 | 2022 | 797 | 0.740 |
Why?
|
Intention | 1 | 2024 | 347 | 0.730 |
Why?
|
Medicare Part D | 3 | 2024 | 355 | 0.730 |
Why?
|
Intellectual Property | 1 | 2020 | 32 | 0.730 |
Why?
|
Cost Savings | 4 | 2024 | 904 | 0.710 |
Why?
|
Duodenoscopes | 1 | 2020 | 43 | 0.710 |
Why?
|
Negotiating | 2 | 2019 | 152 | 0.700 |
Why?
|
Drug Evaluation | 2 | 2018 | 641 | 0.700 |
Why?
|
Abortion, Legal | 1 | 2022 | 121 | 0.690 |
Why?
|
Private Sector | 2 | 2021 | 397 | 0.690 |
Why?
|
Social Control, Formal | 1 | 2020 | 107 | 0.690 |
Why?
|
Tablets | 1 | 2020 | 149 | 0.680 |
Why?
|
Health Insurance Portability and Accountability Act | 2 | 2017 | 105 | 0.670 |
Why?
|
Prescription Fees | 2 | 2018 | 153 | 0.660 |
Why?
|
Drug Prescriptions | 6 | 2022 | 1664 | 0.660 |
Why?
|
Program Development | 2 | 2016 | 1298 | 0.660 |
Why?
|
Drug Labeling | 6 | 2024 | 251 | 0.650 |
Why?
|
Immunization, Secondary | 1 | 2021 | 373 | 0.630 |
Why?
|
Financial Management | 1 | 2020 | 161 | 0.630 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 329 | 0.630 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.630 |
Why?
|
Disinfection | 1 | 2020 | 207 | 0.620 |
Why?
|
Abortion, Induced | 2 | 2023 | 471 | 0.610 |
Why?
|
Humans | 115 | 2024 | 767040 | 0.600 |
Why?
|
Marketing of Health Services | 1 | 2019 | 151 | 0.600 |
Why?
|
Employee Retirement Income Security Act | 1 | 2018 | 9 | 0.600 |
Why?
|
Judicial Role | 1 | 2018 | 38 | 0.590 |
Why?
|
Medicaid | 3 | 2022 | 2836 | 0.590 |
Why?
|
Hematinics | 1 | 2020 | 282 | 0.580 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.580 |
Why?
|
Privacy | 2 | 2017 | 233 | 0.570 |
Why?
|
Marketing | 5 | 2023 | 225 | 0.570 |
Why?
|
Off-Label Use | 3 | 2017 | 185 | 0.570 |
Why?
|
Bioethical Issues | 2 | 2015 | 119 | 0.560 |
Why?
|
Consumer Product Safety | 2 | 2015 | 122 | 0.550 |
Why?
|
Opioid-Related Disorders | 3 | 2021 | 2188 | 0.520 |
Why?
|
Supreme Court Decisions | 1 | 2018 | 135 | 0.520 |
Why?
|
Erythropoietin | 1 | 2020 | 718 | 0.520 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2020 | 348 | 0.510 |
Why?
|
Fentanyl | 1 | 2019 | 451 | 0.500 |
Why?
|
Perception | 2 | 2019 | 1205 | 0.490 |
Why?
|
Therapeutic Equivalency | 4 | 2021 | 135 | 0.480 |
Why?
|
Cost Control | 4 | 2019 | 627 | 0.480 |
Why?
|
Health Care Reform | 3 | 2019 | 1256 | 0.470 |
Why?
|
Research | 3 | 2020 | 1977 | 0.470 |
Why?
|
Antirheumatic Agents | 2 | 2021 | 1379 | 0.460 |
Why?
|
Device Approval | 1 | 2015 | 164 | 0.440 |
Why?
|
Health Policy | 5 | 2017 | 2698 | 0.430 |
Why?
|
Benzoates | 1 | 2014 | 213 | 0.430 |
Why?
|
Dermatologic Agents | 2 | 2019 | 314 | 0.420 |
Why?
|
Hydrazines | 1 | 2014 | 223 | 0.420 |
Why?
|
Disclosure | 1 | 2019 | 755 | 0.420 |
Why?
|
Thrombopoietin | 1 | 2014 | 225 | 0.410 |
Why?
|
Databases as Topic | 1 | 2014 | 472 | 0.410 |
Why?
|
Thrombocytopenia | 2 | 2011 | 1172 | 0.410 |
Why?
|
Salaries and Fringe Benefits | 1 | 2015 | 263 | 0.410 |
Why?
|
Immunologic Factors | 1 | 2022 | 1592 | 0.400 |
Why?
|
Medical Records | 1 | 2017 | 1409 | 0.390 |
Why?
|
Databases, Factual | 6 | 2024 | 8068 | 0.390 |
Why?
|
Anticonvulsants | 1 | 2022 | 1921 | 0.380 |
Why?
|
Patient Education as Topic | 1 | 2022 | 2337 | 0.380 |
Why?
|
Risk | 3 | 2020 | 9606 | 0.370 |
Why?
|
Antiviral Agents | 2 | 2021 | 3070 | 0.370 |
Why?
|
Receptors, Fc | 1 | 2014 | 537 | 0.370 |
Why?
|
Product Surveillance, Postmarketing | 3 | 2020 | 463 | 0.370 |
Why?
|
Anemia | 1 | 2020 | 1514 | 0.360 |
Why?
|
Insurance, Health, Reimbursement | 3 | 2021 | 388 | 0.360 |
Why?
|
Analgesics, Opioid | 4 | 2021 | 3837 | 0.350 |
Why?
|
Medication Adherence | 2 | 2020 | 2191 | 0.350 |
Why?
|
Drug Utilization | 3 | 2022 | 1190 | 0.340 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 3928 | 0.330 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2666 | 0.320 |
Why?
|
Qualitative Research | 1 | 2020 | 3139 | 0.320 |
Why?
|
Communication | 2 | 2020 | 3904 | 0.320 |
Why?
|
Health Care Costs | 3 | 2020 | 3239 | 0.320 |
Why?
|
Splenectomy | 1 | 2010 | 390 | 0.320 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 8048 | 0.320 |
Why?
|
Policy | 2 | 2024 | 513 | 0.310 |
Why?
|
Patient Participation | 1 | 2017 | 1444 | 0.300 |
Why?
|
Drug Discovery | 1 | 2016 | 1068 | 0.300 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1119 | 0.300 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3232 | 0.300 |
Why?
|
Civil Rights | 2 | 2022 | 130 | 0.300 |
Why?
|
Medicare | 8 | 2023 | 6813 | 0.290 |
Why?
|
Information Dissemination | 1 | 2014 | 1142 | 0.260 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3738 | 0.260 |
Why?
|
Insulin | 1 | 2020 | 6602 | 0.250 |
Why?
|
Investments | 2 | 2024 | 148 | 0.250 |
Why?
|
Risk Assessment | 4 | 2024 | 24299 | 0.240 |
Why?
|
United States Federal Trade Commission | 1 | 2024 | 10 | 0.230 |
Why?
|
Pandemics | 3 | 2023 | 8736 | 0.230 |
Why?
|
Policy Making | 2 | 2020 | 546 | 0.230 |
Why?
|
Hepatitis C | 1 | 2014 | 1594 | 0.230 |
Why?
|
Phenylpropionates | 1 | 2024 | 34 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 10393 | 0.230 |
Why?
|
Pyrazoles | 1 | 2014 | 2028 | 0.230 |
Why?
|
Chronic Disease | 1 | 2019 | 9362 | 0.220 |
Why?
|
Europe | 3 | 2020 | 3432 | 0.220 |
Why?
|
Politics | 2 | 2022 | 822 | 0.220 |
Why?
|
Thromboembolism | 1 | 2010 | 1003 | 0.210 |
Why?
|
Canada | 4 | 2022 | 2127 | 0.210 |
Why?
|
Vigabatrin | 1 | 2023 | 88 | 0.210 |
Why?
|
Liver Function Tests | 1 | 2024 | 526 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.200 |
Why?
|
Pyridazines | 1 | 2024 | 199 | 0.200 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5886 | 0.200 |
Why?
|
Time Factors | 7 | 2021 | 40154 | 0.200 |
Why?
|
Australia | 3 | 2021 | 1263 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3234 | 0.200 |
Why?
|
Torsades de Pointes | 1 | 2022 | 78 | 0.180 |
Why?
|
Menstruation-Inducing Agents | 1 | 2020 | 2 | 0.180 |
Why?
|
Epoetin Alfa | 1 | 2020 | 78 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5389 | 0.180 |
Why?
|
Cross-Sectional Studies | 9 | 2024 | 26325 | 0.180 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 63 | 0.180 |
Why?
|
Germany | 2 | 2020 | 882 | 0.170 |
Why?
|
Drug Recalls | 1 | 2020 | 20 | 0.170 |
Why?
|
Biomedical Research | 1 | 2015 | 3464 | 0.170 |
Why?
|
Female | 21 | 2024 | 396660 | 0.170 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2011 | 4349 | 0.170 |
Why?
|
Blood Platelets | 1 | 2010 | 2464 | 0.170 |
Why?
|
Gatekeeping | 1 | 2019 | 49 | 0.170 |
Why?
|
Equipment Contamination | 1 | 2020 | 183 | 0.160 |
Why?
|
Jurisprudence | 1 | 2019 | 109 | 0.160 |
Why?
|
Lawyers | 1 | 2019 | 39 | 0.160 |
Why?
|
Thalidomide | 1 | 2024 | 886 | 0.160 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2020 | 497 | 0.160 |
Why?
|
Compassionate Use Trials | 1 | 2018 | 50 | 0.150 |
Why?
|
Risk Management | 1 | 2022 | 558 | 0.150 |
Why?
|
Health Planning | 1 | 2019 | 233 | 0.150 |
Why?
|
Insurance Claim Review | 2 | 2020 | 744 | 0.150 |
Why?
|
Therapies, Investigational | 1 | 2018 | 110 | 0.140 |
Why?
|
Pharmacies | 1 | 2019 | 171 | 0.140 |
Why?
|
Long QT Syndrome | 1 | 2022 | 473 | 0.140 |
Why?
|
Universities | 1 | 2022 | 1004 | 0.140 |
Why?
|
History, 21st Century | 3 | 2018 | 1574 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 686 | 0.140 |
Why?
|
Diabetic Ketoacidosis | 1 | 2020 | 252 | 0.140 |
Why?
|
Platelet Count | 2 | 2010 | 784 | 0.140 |
Why?
|
Aged | 14 | 2024 | 171319 | 0.140 |
Why?
|
Secondary Prevention | 1 | 2023 | 1472 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1214 | 0.130 |
Why?
|
Cytokines | 1 | 2011 | 7446 | 0.130 |
Why?
|
Insurance, Health | 2 | 2019 | 2519 | 0.130 |
Why?
|
Cholic Acid | 1 | 2015 | 30 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.130 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5537 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12250 | 0.130 |
Why?
|
Chondroitinsulfatases | 1 | 2015 | 16 | 0.130 |
Why?
|
Adult | 14 | 2024 | 223317 | 0.130 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2022 | 616 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2021 | 812 | 0.130 |
Why?
|
Neoplasms | 3 | 2024 | 22350 | 0.120 |
Why?
|
Pharmaceutical Services | 1 | 2017 | 145 | 0.120 |
Why?
|
Vaccines | 1 | 2024 | 842 | 0.120 |
Why?
|
Ethanolamines | 1 | 2015 | 152 | 0.120 |
Why?
|
Quality Control | 1 | 2018 | 835 | 0.120 |
Why?
|
Antiprotozoal Agents | 1 | 2015 | 93 | 0.120 |
Why?
|
Phosphorylcholine | 1 | 2015 | 152 | 0.120 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2020 | 424 | 0.120 |
Why?
|
Models, Economic | 1 | 2019 | 719 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1856 | 0.120 |
Why?
|
New York | 1 | 2017 | 879 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13491 | 0.120 |
Why?
|
Male | 15 | 2024 | 364203 | 0.120 |
Why?
|
Hemoglobins | 1 | 2020 | 1531 | 0.120 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.120 |
Why?
|
United States Dept. of Health and Human Services | 1 | 2014 | 88 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 4054 | 0.110 |
Why?
|
Professional Role | 1 | 2017 | 315 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2020 | 804 | 0.110 |
Why?
|
Drug Design | 1 | 2019 | 1045 | 0.110 |
Why?
|
Artemisinins | 1 | 2015 | 217 | 0.110 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13650 | 0.110 |
Why?
|
Anemia, Sickle Cell | 1 | 2022 | 1065 | 0.110 |
Why?
|
Pregnancy | 4 | 2024 | 30238 | 0.100 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2020 | 1065 | 0.100 |
Why?
|
Rheumatic Diseases | 1 | 2020 | 659 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1405 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 800 | 0.100 |
Why?
|
Cohort Studies | 6 | 2022 | 41718 | 0.100 |
Why?
|
Lower Extremity | 1 | 2020 | 1217 | 0.100 |
Why?
|
Informed Consent | 1 | 2018 | 1010 | 0.100 |
Why?
|
Public Health | 2 | 2022 | 2681 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2021 | 1188 | 0.090 |
Why?
|
Fever | 1 | 2019 | 1605 | 0.090 |
Why?
|
Warfarin | 1 | 2020 | 1493 | 0.090 |
Why?
|
Meta-Analysis as Topic | 2 | 2018 | 1364 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1761 | 0.090 |
Why?
|
Recombinant Proteins | 1 | 2020 | 6507 | 0.090 |
Why?
|
Benzodiazepines | 1 | 2017 | 1137 | 0.090 |
Why?
|
Indium Radioisotopes | 1 | 2010 | 114 | 0.090 |
Why?
|
Hemorrhagic Disorders | 1 | 2010 | 34 | 0.090 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 724 | 0.090 |
Why?
|
Receptors, Cytokine | 1 | 2011 | 258 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3883 | 0.090 |
Why?
|
Middle Aged | 10 | 2024 | 223233 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 2007 | 0.080 |
Why?
|
Drug Combinations | 1 | 2015 | 2086 | 0.080 |
Why?
|
Young Adult | 5 | 2024 | 59980 | 0.080 |
Why?
|
Antimalarials | 1 | 2015 | 909 | 0.080 |
Why?
|
Quality of Life | 1 | 2010 | 13485 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 3108 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2062 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1946 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2341 | 0.070 |
Why?
|
Antitubercular Agents | 1 | 2015 | 1380 | 0.070 |
Why?
|
Length of Stay | 1 | 2020 | 6489 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7848 | 0.070 |
Why?
|
Radionuclide Imaging | 1 | 2010 | 1987 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2936 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10622 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1326 | 0.060 |
Why?
|
Logistic Models | 1 | 2020 | 13284 | 0.060 |
Why?
|
Survival Rate | 1 | 2019 | 12823 | 0.060 |
Why?
|
Cell Death | 1 | 2010 | 1677 | 0.060 |
Why?
|
Helicobacter pylori | 1 | 2008 | 380 | 0.060 |
Why?
|
Helicobacter Infections | 1 | 2008 | 390 | 0.060 |
Why?
|
Adolescent | 4 | 2024 | 89046 | 0.060 |
Why?
|
Spleen | 1 | 2010 | 2292 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2019 | 4881 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2020 | 65295 | 0.060 |
Why?
|
Anticoagulants | 1 | 2020 | 4854 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8351 | 0.060 |
Why?
|
Age Factors | 1 | 2020 | 18401 | 0.050 |
Why?
|
Disease Susceptibility | 1 | 2010 | 1791 | 0.050 |
Why?
|
Hydroxyzine | 1 | 2022 | 2 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2023 | 81659 | 0.050 |
Why?
|
Preoperative Care | 1 | 2010 | 2252 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5180 | 0.050 |
Why?
|
Legislation as Topic | 1 | 2021 | 76 | 0.040 |
Why?
|
Health Surveys | 1 | 2010 | 4056 | 0.040 |
Why?
|
Alleles | 1 | 2011 | 6893 | 0.040 |
Why?
|
European Union | 1 | 2020 | 158 | 0.040 |
Why?
|
Medicare Part C | 1 | 2024 | 333 | 0.040 |
Why?
|
Life Style | 1 | 2010 | 3931 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9245 | 0.040 |
Why?
|
Sertraline | 1 | 2019 | 210 | 0.040 |
Why?
|
Isotretinoin | 1 | 2019 | 135 | 0.040 |
Why?
|
History, 20th Century | 2 | 2015 | 2765 | 0.030 |
Why?
|
Uncertainty | 1 | 2021 | 765 | 0.030 |
Why?
|
Child | 3 | 2024 | 80771 | 0.030 |
Why?
|
Citalopram | 1 | 2019 | 402 | 0.030 |
Why?
|
State Medicine | 1 | 2017 | 219 | 0.030 |
Why?
|
HIV Infections | 1 | 2021 | 17542 | 0.030 |
Why?
|
Conflict of Interest | 1 | 2020 | 556 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 2030 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22254 | 0.030 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1604 | 0.030 |
Why?
|
Thiazolidinediones | 1 | 2016 | 460 | 0.030 |
Why?
|
Phenylcarbamates | 1 | 2011 | 38 | 0.020 |
Why?
|
Fish Oils | 1 | 2015 | 483 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 16036 | 0.020 |
Why?
|
Incidence | 1 | 2010 | 21526 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1971 | 0.020 |
Why?
|
Health Services Research | 1 | 2018 | 1815 | 0.020 |
Why?
|
Prognosis | 1 | 2010 | 29963 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 18063 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2210 | 0.020 |
Why?
|
Electrocardiography | 1 | 2022 | 6409 | 0.020 |
Why?
|
Sample Size | 1 | 2011 | 845 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 12793 | 0.020 |
Why?
|
Hemorrhage | 1 | 2020 | 3464 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1883 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5186 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2022 | 14766 | 0.020 |
Why?
|
Behavior Therapy | 1 | 2011 | 886 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2022 | 9612 | 0.010 |
Why?
|
Neuroprotective Agents | 1 | 2011 | 956 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 59548 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3249 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6210 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2698 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2011 | 2745 | 0.010 |
Why?
|
Odds Ratio | 1 | 2011 | 9660 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39317 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6260 | 0.010 |
Why?
|
Dementia | 1 | 2011 | 2741 | 0.010 |
Why?
|
Risk Factors | 1 | 2020 | 74886 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15645 | 0.010 |
Why?
|